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Abstract: BACKGROUND Among patients with stable coronary disease and moderate or severe is-
chemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical
therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned
5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revas-
cularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy
alone and angiography if medical therapy failed. The primary outcome was a composite of death from
cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or re-
suscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial
infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-
strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event
rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9
percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was
16.4% and 18.2%, respectively (difference, -1.8 percentage points; 95% CI, -4.7 to 1.0). Results were
similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive
to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial in-
farctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144
deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS
Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence
that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of
ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings
were sensitive to the definition of myocardial infarction that was used. (Funded by the National Heart,
Lung, and Blood Institute and others; ISCHEMIA ClinicalTrials.gov number, NCT01471522.).
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BACKGROUND
Among patients with stable coronary disease and moderate or severe ischemia, 
whether clinical outcomes are better in those who receive an invasive intervention 
plus medical therapy than in those who receive medical therapy alone is uncertain.
METHODS
We randomly assigned 5179 patients with moderate or severe ischemia to an initial 
invasive strategy (angiography and revascularization when feasible) and medical 
therapy or to an initial conservative strategy of medical therapy alone and angiog-
raphy if medical therapy failed. The primary outcome was a composite of death 
from cardiovascular causes, myocardial infarction, or hospitalization for unstable 
angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was 
death from cardiovascular causes or myocardial infarction.
RESULTS
Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-
strategy group and 352 occurred in the conservative-strategy group. At 6 months, 
the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the 
conservative-strategy group (difference, 1.9 percentage points; 95% confidence 
interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, 
respectively (difference, −1.8 percentage points; 95% CI, −4.7 to 1.0). Results were 
similar with respect to the key secondary outcome. The incidence of the primary 
outcome was sensitive to the definition of myocardial infarction; a secondary 
analysis yielded more procedural myocardial infarctions of uncertain clinical im-
portance. There were 145 deaths in the invasive-strategy group and 144 deaths in 
the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32).
CONCLUSIONS
Among patients with stable coronary disease and moderate or severe ischemia, we 
did not find evidence that an initial invasive strategy, as compared with an initial 
conservative strategy, reduced the risk of ischemic cardiovascular events or death 
from any cause over a median of 3.2 years. The trial findings were sensitive to the 
definition of myocardial infarction that was used. (Funded by the National Heart, 
Lung, and Blood Institute and others; ISCHEMIA ClinicalTrials.gov number, 
NCT01471522.)
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T
he goals of treating patients with 
stable coronary disease are to reduce their 
risk of death and ischemic events and to 
improve their quality of life. All patients with 
coronary disease should be treated with guide-
line-based medical therapy (hereafter, medical 
therapy) to achieve these objectives.1,2 Before the 
widespread availability of drug-eluting stents, 
strategy trials that tested the incremental effect 
of revascularization added to medical therapy did 
not show a reduction in the incidence of death 
or myocardial infarction.3,4 In one trial, fractional 
flow reserve–guided percutaneous coronary in-
tervention (PCI) with drug-eluting stents, added 
to medical therapy, decreased the incidence of 
urgent revascularization but not the incidence of 
death from any cause or myocardial infarction at 
a mean of 7 months,5 whereas the 5-year follow-
up showed marginal evidence of a decrease in 
the incidence of myocardial infarction.6
Several theories have been advanced to explain 
why previous strategy trials involving patients with 
stable coronary disease have not shown a decrease 
in death or myocardial infarction with revascu-
larization. In trials requiring angiographic evi-
dence of obstructive coronary disease, patients 
with high-risk anatomical features may have been 
excluded and knowledge of the anatomy may have 
led to revascularization in patients who were ran-
domly assigned to a conservative strategy. Previ-
ous studies allowed the enrollment of patients with 
any level of ischemia, which resulted in a minority 
of patients with moderate or severe ischemia for 
whom an invasive strategy might have been most 
beneficial. In a single-center observational study 
involving 10,627 patients, the incidence of death 
from cardiac causes was lower among those with 
at least 10% ischemia on myocardial perfusion 
imaging who underwent early revascularization 
than among those who did not undergo revascu-
larization.7 We designed the International Study 
of Comparative Health Effectiveness with Medical 
and Invasive Approaches (ISCHEMIA) to determine 
the effect of adding cardiac catheterization (here-
after, angiography) and revascularization when 
feasible to medical therapy in patients with stable 
coronary disease and moderate or severe ischemia.8,9
Me thods
Trial Population
The trial design and baseline characteristics of the 
patients have been described previously.8,10 Patients 
with stable coronary disease were enrolled at clini-
cal sites that met certain quality metrics (see the 
Methods section in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org) after clinically indicated stress testing 
showed moderate or severe reversible ischemia on 
imaging tests or severe ischemia on exercise tests 
without imaging (Fig. S1 and S2 in the Supple-
mentary Appendix). The option of exercise-stress 
testing without imaging was added as a protocol 
addendum in 2014 to improve recruitment and 
generalizability of the trial results.11 Key exclusion 
criteria were an estimated glomerular filtration 
rate below 30 ml per minute per 1.73 m2 of body-
surface area, a recent acute coronary syndrome, 
unprotected left main stenosis of at least 50%, a 
left ventricular ejection fraction of less than 35%, 
New York Heart Association class III or IV heart 
failure, and unacceptable angina despite the use 
of medical therapy at maximum acceptable doses.
Most enrolled trial patients underwent coro-
nary computed tomographic (CT) angiography to 
rule out left main coronary disease and nonob-
structive coronary disease. The primary exceptions 
to the use of CT angiography were renal dysfunc-
tion that would preclude such testing or known 
coronary anatomy. Patients underwent random-
ization if protocol-indicated clinical, ischemia-
based, and anatomical eligibility criteria (based on 
blinded CT angiography) had been met (Tables S1 
and S2). Although sites determined whether stress-
testing results met eligibility criteria for ischemia 
severity, all stress tests were reviewed by indepen-
dent core laboratories.
Treatment Strategies
Eligible patients were randomly assigned, in a 1:1 
ratio, to an initial invasive strategy of medical 
therapy, angiography, and revascularization when 
feasible or to an initial conservative strategy of 
medical therapy alone, with angiography reserved 
for failure of medical therapy. Randomization was 
performed with an interactive voice–response or 
Web-based response system with the use of ran-
domly permuted blocks of varying sizes, with 
stratification according to enrollment site.
Patients who were assigned to the invasive strat-
egy were to undergo angiography within 30 days 
after randomization and complete revasculariza-
tion of all ischemic territories if feasible. Sites were 
provided with guidelines for performing revascu-
larization, including the use of fractional flow 
reserve measurements when available and appro-
A Quick Take is 
available at 
NEJM.org 
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priate (Fig. S3a and S3b and the Supplementary 
Methods section). Decisions about the type of re-
vascularization — PCI or coronary-artery bypass 
grafting (CABG) — were deferred to the local 
heart team. An independent angiographic core 
laboratory analyzed all protocol-assigned angio-
graphic and PCI procedures. Medical therapy con-
sisted of intensive secondary prevention with life-
style and pharmacologic interventions applied 
equally in both groups with the use of treat-to-
target algorithms (Table S3). Patients were fol-
lowed at 1.5, 3, 6, and 12 months after random-
ization and every 6 months thereafter.
Outcome Assessment
The primary outcome was the composite of death 
from cardiovascular causes, myocardial infarction, 
or hospitalization for unstable angina, heart fail-
ure, or resuscitated cardiac arrest. The key sec-
ondary outcomes were the composite of death 
from cardiovascular causes or myocardial infarc-
tion and angina-related quality of life. Clinical 
outcomes were adjudicated by an independent 
clinical-event committee whose members were 
unaware of the trial-group assignments.
The primary definition of nonprocedural in-
farction was based on the Third Universal Defi-
nition of Myocardial Infarction types 1, 2, 4b, and 
4c.12 For procedural infarctions, we required higher 
biomarker thresholds for confirmation8 because 
data showed that this more stringent definition 
carried greater prognostic significance than the 
universal definition types 4a and 5.13,14 We devel-
oped a secondary definition for procedural in-
farctions that used biomarker thresholds that were 
similar to those of the universal definition but 
with additional criteria based on elevations of bio-
marker levels alone without additional findings. 
Definitions of all trial outcomes, including both 
the primary and the secondary definitions of pro-
cedural infarction, are provided in the Supplemen-
tary Methods section.
Trial Organization and Oversight
The trial was designed by the executive committee 
and sponsored by the National Heart, Lung, and 
Blood Institute, with additional support from in-
dustry sponsors (Table S4). An independent data 
and safety monitoring board approved the trial 
protocol (available at NEJM.org) and monitored 
patient safety. The protocol was approved by the 
institutional review board at New York University 
Grossman School of Medicine (the clinical coor-
dinating center) and by the institutional review 
board and ethics committee at each participating 
site (see the Supplementary Appendix). All the pa-
tients provided written informed consent.
The industry sponsors did not have access to 
the data during the trial and did not participate 
in the trial design, data analysis, or manuscript 
preparation. The statistical and data coordinating 
center at Duke Clinical Research Institute moni-
tored data collection and quality and performed 
statistical analyses. The first author prepared the 
first draft of the manuscript. The first and second 
authors had full access to the data and were re-
sponsible for editing subsequent drafts as well as 
for the decision to submit the final manuscript for 
publication. All the authors vouch for the accuracy 
and completeness of the data and adherence of the 
trial to the protocol.
Statistical Analysis
The original trial design specified that 8000 pa-
tients would undergo randomization with 4 years 
of follow-up for the five-component primary com-
posite outcome reported in this article.15 Before 
the trial launch, the National Heart, Lung, and 
Blood Institute and the data and safety monitoring 
board approved changing the primary outcome to 
a composite of death from cardiovascular causes 
or myocardial infarction, with a protocol-defined 
procedure to revert to the five-component primary 
outcome if needed to preserve statistical power. 
Slow recruitment and lower-than-expected aggre-
gated event rates triggered this prespecified con-
tingency plan and other changes, as described 
previously.8,11
Power calculations performed in 2015 deter-
mined that a trial with 5000 patients would have 
at least 83% power to detect an 18% relative re-
duction in the 4-year rate of the primary outcome, 
assuming a 4-year rate of 20% in the conservative-
strategy group. When power was reestimated with 
the use of updated event-rate assumptions derived 
from blinded trial data in 2018, the final sample 
size was estimated to provide at least 83% power 
to detect an 18.5% relative reduction in the pri-
mary outcome, assuming average follow-up of ap-
proximately 3 years and an aggregate 4-year cu-
mulative incidence of 14%.
Detailed statistical methods are provided in 
the Supplementary Methods section. Group com-
parisons were performed according to the inten-
tion-to-treat principle based on time-to-first-event 
analyses. Cumulative event probabilities were es-
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timated with the use of the Kaplan–Meier method 
for outcomes that were not subject to competing 
risks (e.g., death from any cause) and by a non-
parametric cumulative-incidence function estima-
tor for outcomes that were subject to competing 
risks (e.g., the primary outcome, for which death 
from noncardiovascular causes is a competing 
risk).16 The prespecified primary analysis was a 
covariate-adjusted Cox proportional-hazards mod-
el. However, the proportional-hazards assumption 
underlying the Cox model was not met for the 
primary outcome (P<0.001 for time-by-treatment 
interaction) and several secondary outcomes. We 
report these results for the primary outcome and 
do not report them for any other outcomes that 
show nonproportionality.
The statistical analysis plan specified that pre-
sentation of the results would emphasize non-
parametric cumulative event-rate estimates if the 
proportional-hazards assumption was violated. 
Differences in these estimates for the invasive-
strategy group as compared with the conservative-
strategy group at 6 months and at yearly time 
points were tabulated and presented with 95% 
confidence intervals. The confidence intervals 
have not been adjusted for multiple comparisons, 
so these intervals should not be used to infer de-
finitive treatment effects. In a post hoc analysis, 
we used kernel smoothing to estimate hazard-rate 
functions over time for the two treatment groups.17 
We also estimated the difference in restricted 
mean event-free time over 5 years.18,19 This quan-
tity is derived from the nonparametric cumulative 
event-rate curves and is interpreted as the average 
number of event-free days per patient over the pe-
riod between randomization and 5 years. Support-
ing analyses using a Bayesian statistical frame-
work were prespecified to permit the primary 
clinical results to be expressed in terms of the 
posterior (post-trial) probability of a small or 
large effect size in light of the current trial data. 
We implemented the Bayesian approach using a 
flexible piecewise-exponential nonproportional-
hazards model (see the Supplementary Methods 
section). Analyses were performed with the use of 
SAS software (version 9.4), WinBUGS software 
(version 1.4), and R software (version 3.6).
R esult s
Baseline Characteristics and Medical Therapy
From July 26, 2012, through January 31, 2018, 
a total of 8518 patients were enrolled and 5179 
underwent randomization at 320 sites in 37 coun-
tries (Section II in the Supplementary Appendix 
and Fig. 1). The baseline characteristics of the pa-
tients were well balanced between the two groups 
(Table 1 and Table S5). Baseline risk-factor con-
trol and medication use were similar in the groups 
(Table S6). The median low-density lipoprotein 
cholesterol level was 83 mg per deciliter (2.2 mmol 
per liter) at baseline and 64 mg per deciliter 
(1.7 mmol per liter) at the last visit. Medication 
use at baseline and during follow-up is shown in 
Figures S4 and S5.
Use of Invasive Procedures and Follow-up
Among patients in the invasive-strategy group, 
96% underwent angiography and 79% underwent 
revascularization (PCI in 74% and CABG in 26%) 
(Table S7a and Fig. S6). Angiographic character-
istics of patients in the invasive-strategy group 
and procedural data are provided in Table S8. In 
the conservative-strategy group, 26% of the pa-
tients underwent angiography and 21% underwent 
revascularization; 19% underwent angiography 
and 15% underwent revascularization before the 
occurrence of a primary outcome event. The total 
numbers of invasive procedures, including repeat 
procedures, that were performed in each group 
were 5337 in the invasive-strategy group and 1506 
in the conservative-strategy group (Table S9). Pa-
tients were followed until June 30, 2019; the me-
dian duration of follow-up was 3.2 years.
Primary Outcome
The primary outcome occurred in 318 patients 
in the invasive-strategy group and in 352 patients 
in the conservative-strategy group (Table 2 and 
Fig. 2). In prespecified covariate-adjusted Cox 
model analysis, the estimated hazard ratio with 
the invasive strategy as compared with the conser-
vative strategy was 0.93 (95% confidence interval 
[CI], 0.80 to 1.08; P = 0.34). However, the under-
lying proportional-hazards assumption was vio-
lated. At 6 months, the estimated cumulative event 
rate was 5.3% in the invasive-strategy group and 
3.4% in the conservative-strategy group (differ-
ence, 1.9 percentage points; 95% CI, 0.8 to 3.0). 
At 5 years, the estimated cumulative event rate was 
16.4% in the invasive-strategy group and 18.2% 
in the conservative-strategy group (difference, −1.8 
percentage points; 95% CI, −4.7 to 1.0). The esti-
mated hazard rates over time are shown in Figure 
S7. We did not find evidence of a difference in the 
5-year restricted mean event-free time between 
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the groups (9.5 days longer in the invasive-strategy 
group; 95% CI, −17.8 to 36.9).
Secondary Outcomes
There were 276 deaths from cardiovascular causes 
or myocardial infarctions in the invasive-strategy 
group and 314 in the conservative-strategy group 
(Table 2 and Fig. 2). At 6 months, the estimated 
event rate was 4.8% in the invasive-strategy group 
and 2.9% the conservative-strategy group (differ-
ence, 1.9 percentage points; 95% CI, 0.9 to 3.0). 
At 5 years, the estimated cumulative event rate 
was 14.2% in the invasive-strategy group and 
16.5% in the conservative-strategy group (differ-
ence, −2.3 percentage points; 95% CI, −5.0 to 0.4). 
The restricted mean time free from death from 
cardiovascular causes or infarction over 5 years 
was similar in the two groups (9.4 days longer in 
the invasive-strategy group; 95% CI, −16.5 to 35.2). 
Other outcomes according to treatment group are 
shown in Table 2, Table S10, and Figure S8. There 
were more hospitalizations for heart failure and 
fewer hospitalizations for unstable angina with the 
invasive strategy. There were 145 deaths in the in-
vasive-strategy group and 144 deaths in the conser-
vative-strategy group (hazard ratio, 1.05; 95% CI, 
0.83 to 1.32).
The early increased risk of the primary and 
major secondary outcomes in the invasive-strategy 
group was attributable to more procedural infarc-
tions in early follow-up. This early hazard differ-
ence was increased when the secondary definition 
of infarction, which increased the number of adju-
dicated procedural infarctions, was used. With the 
use of the secondary definition of myocardial in-
farction, the estimated cumulative event rate at 
6 months for the primary outcome was 10.2% in 
the invasive-strategy group and 3.7% in the con-
servative-strategy group (difference, 6.5 percentage 
points; 95% CI, 5.2 to 7.9), and the estimated cu-
mulative event rate at 5 years was 21.2% in the 
invasive-strategy group and 19.0% in the conser-
vative-strategy group (difference, 2.2 percentage 
points; 95% CI, −0.7 to 5.2). The greater number 
of procedural infarctions according to the second-
ary definition is reflected in all composite outcomes 
that include infarctions (Table S11 and Fig. S9).
Heterogeneity of Treatment Effect
No evidence of a differential treatment effect on 
the primary outcome was found for five prespeci-
fied covariates or the degree of ischemia (Fig. 3). 
Likewise, there was no evidence of a differential 
treatment effect on the primary outcome with re-
spect to other baseline characteristics, including 
the type of stress test, baseline left ventricular 
ejection fraction, estimated glomerular filtration 
rate, and age.
Figure 1. Enrollment, Randomization, and Follow-up.
Unprotected left main coronary artery (LMCA) disease was defined as 50% 
or greater LMCA stenosis without a bypass graft to the left coronary artery. 
To maximize information about baseline coronary anatomy, available coro-
nary computed tomographic angiographic (CCTA) images obtained less 
than 1 year before enrollment in 130 patients were subsequently collected 
for CCTA core laboratory review. The percentage of projected follow-up 
completed was calculated with the number of patient-years of observed fol-
low-up as the numerator and the number of patient-years of expected fol-
low-up as the denominator. The percentages of patients who underwent 
angiography and revascularization differ from the cumulative incidence 
function rates, which account for censoring. The percentage of patients 
who underwent angiography includes a small number of patients in the in-
vasive-strategy group who underwent angiography before randomization 
and did not undergo repeat angiography after randomization and before 
bypass surgery. A total of 15% of the patients in the conservative-strategy 
group underwent revascularization before a primary outcome event oc-
curred. CAD denotes coronary artery disease, eGFR estimated glomerular 
filtration rate, and IQR interquartile range.
5179 Underwent randomization
3783 (73.0%) Underwent trial CCTA
1396 (27.0%) Did not undergo trial CCTA
575 Had low eGFR
700 Had known coronary anatomy
121 Had other reason
8518 Patients were enrolled
3339 Were excluded
1350 Did not have moderate or
severe ischemia, according
to stress core laboratory
1218 Did not have obstructive CAD
434 Had unprotected LMCA
disease
2588 Were assigned to invasive
strategy
2591 Were assigned to conservative
strategy
Median follow-up, 3.2 yr
(IQR, 2.1 to 4.3)
99.4% of projected follow-up
was completed
Median follow-up, 3.2 yr
(IQR, 2.2 to 4.3)
99.7% of projected follow-up
was completed
28 (1.1%) Withdrew
36 (1.4%) Were lost to follow-up
2475 (95.6%) Underwent angio-
graphy
2054 (79.4%) Underwent revas-
cularization
22 (0.8%) Withdrew
26 (1.0%) Were lost to follow-up
667 (25.7%) Underwent angio-
graphy
544 (21.0%) Underwent revas-
cularization
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Bayesian Analysis
In the Bayesian analysis, the post-trial probability 
that the difference in group-specific 5-year cumula-
tive rates of the primary outcome is greater than 
3 absolute percentage points was estimated to be 
24.5% for a difference favoring the invasive strategy 
and less than 0.1% for a difference favoring the 
conservative strategy; results were similar for the 
key secondary outcome (Fig. S10 and Table S12). 
The probability that the difference in the 5-year rate 
of death from any cause is greater than 1 absolute 
percentage point was estimated to be 10.7% for a 
difference favoring the invasive strategy and 32.1% 
for a difference favoring the conservative strategy.
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Invasive Strategy 




 (N = 5179)
Median age (IQR) — yr 64 (58–70) 64 (58–70) 64 (58–70)
Male sex — no. (%) 1982 (76.6) 2029 (78.3) 4011 (77.4)
Race or ethnic group — no./total no. (%)†
White 1706/2569 (66.4) 1697/2560 (66.3) 3403/5129 (66.3)
Black 96/2569 (3.7) 108/2560 (4.2) 204/5129 (4.0)
Asian 747/2569 (29.1) 738/2560 (28.8) 1485/5129 (29.0)
Hispanic or Latino 372/2402 (15.5) 391/2413 (16.2) 4815 (15.8)
Other or multiple ethnic groups 20/2569 (0.8) 17/2560 (0.7) 37/5129 (0.7)
Hypertension — no./total no. (%) 1894/2579 (73.4) 1895/2582 (73.4) 3789/5161 (73.4)
Diabetes — no. (%) 1071 (41.4) 1093 (42.2) 2164 (41.8)
Use of insulin — no. (%) 239 (9.2) 253 (9.8) 492 (9.5)
Cigarette smoking — no./total no. (%)
Never smoked 1119/2587 (43.3) 1089/2587 (42.1) 2208/5174 (42.7)
Former smoker 1149/2587 (44.4) 1177/2587 (45.5) 2326/5174 (45.0)
Current smoker 319/2587 (12.3) 321/2587 (12.4) 640/5174 (12.4)
Family history of premature coronary artery disease — no./
total no. (%)
578/2228 (25.9) 592/2262 (26.2) 1170/4490 (26.1)
Previous myocardial infarction — no./total no. (%) 495/2580 (19.2) 496/2582 (19.2) 991/5162 (19.2)
Previous PCI — no./total no. (%) 551/2586 (21.3) 499/2589 (19.3) 1050/5175 (20.3)
Previous CABG — no./total no. (%) 110/2588 (4.3) 93/2591 (3.6) 203/5179 (3.9)
Cardiac catheterization — no./total no. (%)
Before enrollment 979/2588 (37.8) 925/2591 (35.7) 1904/5179 (36.8)
Before enrollment and ≤12 mo before randomization 338/2504 (13.5) 329/2503 (13.1) 667/5007 (13.3)
CCTA — no./total no. (%)
Before enrollment 178/2585 (6.9) 175/2588 (6.8) 353/5173 (6.8)
Before enrollment and ≤12 mo before randomization 127/2573 (4.9) 126/2576 (4.9) 253/5149 (4.9)
Heart failure — no. (%)
History 112 (4.3) 94 (3.6) 206 (4.0)
Previous hospitalization 27 (1.0) 30 (1.2) 57 (1.1)
Median ejection fraction (IQR) — % 60 (55–65) 60 (55–65) 60 (55–65)
History of atrial fibrillation or atrial flutter — no./total no. 
(%)
128/2587 (4.9) 93/2586 (3.6) 221/5173 (4.3)
Previous stroke — no./total no. (%) 83/2587 (3.2) 68/2591 (2.6) 151/5178 (2.9)
History of cerebrovascular disease — no./total no. (%)‡ 201/2582 (7.8) 176/2583 (6.8) 377/5165 (7.3)
History of peripheral-artery disease — no./total no. (%) 116/2585 (4.5) 88/2583 (3.4) 204/5168 (3.9)
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Discussion
Over a median of 3.2 years of follow-up, among 
patients with stable coronary disease who had 
moderate or severe ischemia on stress testing, 
an initial invasive strategy, as compared with an 
initial conservative strategy, did not reduce the 
rates of the primary or key secondary composite 
outcomes. Patients in the invasive-strategy group 
had more procedural infarctions, and they had 
fewer nonprocedural infarctions during follow-
up. The incidence of death from any cause was 
low and similar in the two groups.
The opposing trends in procedural and non-
procedural infarctions drove the lack of propor-
tionality for the primary and key secondary 
outcomes. The rate of early cardiovascular events 
was higher and the rate of late cardiovascular 
events was lower among patients in the invasive-
strategy group than among those in the conser-
vative-strategy group. Differences in event rates 
between the groups in early follow-up were greater 
when the secondary definition of procedural in-
farction was used; this showed the sensitivity of 
rates of procedural infarctions to the definition 
used. The invasive strategy was associated with 
fewer nonprocedural infarctions when either def-
inition was used. When the secondary definition 
of myocardial infarction was used, the primary 
outcome occurred more frequently in the invasive-
strategy group than in the conservative-strategy 
group throughout the 5-year follow-up period.
A preliminary analysis of ISCHEMIA data pro-
vides support for previous studies showing that 
spontaneous infarctions confer a higher risk of 
subsequent death than procedural infarctions.13,14 
Despite pronounced differences in the frequency 
and timing of myocardial infarctions, there was 
no difference between the groups with respect to 
mortality. Longer-term follow-up with assessment 
of mortality is needed to fully understand the 
prognostic implications of more procedural and 
fewer nonprocedural infarctions with an invasive 
strategy.
The results of ISCHEMIA should be interpret-
ed in the context of certain limitations. Power 
was decreased by reducing the sample size from 
8000 to 5179 patients, event rates were lower than 
expected, and the period of follow-up was modest. 
With a 3.2-year median follow-up, event-rate esti-
mates past the median are subject to progressively 
greater uncertainty. The primary outcome was 
expanded, as prespecified, owing to slow recruit-
ment, yet there was no difference between the 
results for the primary and key secondary out-
comes. The findings do not apply to patients with 
Characteristic
Invasive Strategy 




 (N = 5179)
Angina
History — no./total no. (%) 2329/2588 (90.0) 2312/2591 (89.2) 4641/5179 (89.6)
Began or became more frequent within previous 3 mo 
— no./total no. (%)
680/2584 (26.3) 675/2583 (26.1) 1355/5167 (26.2)
New onset within previous 3 mo — no./total no. (%) 415/2452 (16.9) 440/2466 (17.8) 855/4918 (17.4)
SAQ Angina Frequency score§ 80.7±20.0 82.1±19.2 81.4±19.6
Daily or weekly angina — no./total no. (%)§ 502/2314 (21.7) 442/2333 (18.9) 944/4647 (20.3)
Angina several times per mo — no./total no. (%)§ 1018/2314 (44.0) 1039/2333 (44.5) 2057/4647 (44.3)
No angina in previous 4 wk — no./total no. (%)§ 794/2314 (34.3) 852/2333 (36.5) 1646/4647 (35.4)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. CCTA denotes coronary computed tomographic 
angiography, and IQR interquartile range.
†  Race or ethnic group was reported by the patient.
‡  Previous cerebrovascular disease is defined as a previous carotid artery surgery or stent placement, a previous stroke, or a previous tran-
sient ischemic attack.
§  The Seattle Angina Questionnaire (SAQ) captures the frequency of angina and the disease-specific effect of angina on patients’ physical 
function and quality of life; the subscales are averaged to define the SAQ summary score. SAQ scores range from 0 to 100, with higher 
scores indicating less frequent angina, better function, and greater quality of life. For the SAQ Angina Frequency scale, scores of 0 to 30, 
31 to 60, 61 to 99, and 100 have been shown to validly reflect angina that occurs daily, weekly, monthly, and no angina, respectively, as as-
sessed with daily diaries. Data were excluded from five sites (481 patients) because of improper completion of forms.
Table 1. (Continued.)
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No. of patients with events 318 352
Cumulative event rate — % 0.93 (0.80 to 1.08)
At 6 mo 5.3 3.4 1.9 (0.8 to 3.0)
At 1 yr 7.0 5.4 1.5 (0.2 to 2.9)
At 2 yr 9.0 9.5 −0.5 (−2.1 to 1.1)
At 3 yr 11.3 12.7 −1.3 (−3.2 to 0.6)
At 4 yr 13.3 15.5 −2.2 (−4.4 to 0)
At 5 yr 16.4 18.2 −1.8 (−4.7 to 1.0)
Restricted mean event-free time 4.5 yr 4.5 yr 9.5 days (−17.8 to 36.9)
Death from cardiovascular causes  
or myocardial infarction
No. of patients with events 276 314
Cumulative event rate — %
At 6 mo 4.8 2.9 1.9 (0.9 to 3.0)
At 1 yr 6.2 4.6 1.6 (0.4 to 2.8)
At 2 yr 7.9 8.2 −0.3 (−1.8 to 1.2)
At 3 yr 9.7 11.0 −1.3 (−3.1 to 0.5)
At 4 yr 11.7 13.9 −2.2 (−4.4 to −0.1)
At 5 yr 14.2 16.5 −2.3 (−5.0 to 0.4)
Restricted mean event-free time 4.6 yr 4.5 yr 9.4 days (−16.5 to 35.2)
Death from any cause
No. of patients with events 145 144
Cumulative event rate — % 1.05 (0.83 to 1.32)
At 6 mo 0.8 0.4 0.4 (−0 to 0.8)
At 1 yr 1.7 1.0 0.7 (0 to 1.3)
At 2 yr 2.8 2.9 −0.1 (−1.0 to 0.9)
At 3 yr 4.3 4.3 0 (−1.2 to 1.2)
At 4 yr 6.5 6.4 0.1 (−1.5 to 1.8)
At 5 yr 9.0 8.3 0.7 (-1.6 to 3.1)
Restricted mean event-free time 4.8 yr 4.8 yr −3.0 days (−19.6 to 13.6)
Myocardial infarction
No. of patients with events 210 233
Cumulative event rate — %
At 6 mo 4.3 2.6 1.8 (0.8 to 2.8)
At 1 yr 5.3 3.8 1.5 (0.3 to 2.6)
At 2 yr 6.3 6.5 −0.1 (−1.5 to 1.2)
At 3 yr 7.7 8.5 −0.7 (−2.3 to 0.8)
At 4 yr 8.9 10.1 −1.2 (−3.0 to 0.6)
At 5 yr 10.3 11.9 −1.6 (−3.9 to 0.7)
Restricted mean event-free time 4.6 yr 4.6 yr 3.2 days (−20.3 to 26.7)
*  CI denotes confidence interval.
†  The hazard ratio for the invasive strategy as compared with the conservative strategy is shown, with adjustment for age, sex, estimated glo-
merular filtration rate, ejection fraction, and diabetes. The prespecified primary analysis was a covariate-adjusted Cox proportional-hazards 
model. Hazard ratios are presented for the primary outcome and for death from any cause; the latter is an outcome that appears to satisfy 
the proportional-hazards assumption. The 95% confidence intervals have not been adjusted for multiple comparisons, and therefore these 
intervals should not be used to infer definitive treatment effects.
‡  The primary composite outcome was death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart 
failure, or resuscitated cardiac arrest.
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acute coronary syndromes,18,19 clinically signifi-
cant left main coronary artery disease,20,21 low 
ejection fraction,22 class III or IV heart failure, or 
those who are very symptomatic despite the use 
of medical therapy at maximum acceptable 
doses. Although the stress core laboratories did 
not confirm that the degree of ischemia was suf-
ficient to qualify for the trial in 14% of the pa-
tients who underwent randomization, a sub-
group analysis showed that inclusion of patients 
with less than moderate ischemia as determined 
by core laboratories had no effect on the trial 
findings. We have not yet analyzed the effect of 
the completeness23 or method24 of revasculariza-
tion on outcomes. The clinical outcomes should 
be interpreted in the context of quality-of-life 
outcomes, which represent a different dimension 
of treatment effectiveness and are reported sepa-
rately.25
In conclusion, we compared an initial inva-
sive strategy with an initial conservative strategy 
in patients with coronary disease and moderate 
Figure 2. Time-to-Event Curves for the Primary Composite Outcome and Other Outcomes.
Panel A shows the cumulative incidence of the primary composite outcome of death from cardiovascular causes, myocardial infarction, 
or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest in the conservative-strategy group and the invasive-
strategy group. Panel B shows the cumulative incidence of death from cardiovascular causes or myocardial infarction. Panel C shows the 
cumulative incidence of death from any cause, and Panel D shows the cumulative incidence of myocardial infarction. In each panel, the 
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or severe ischemia. We did not find evidence that 
the initial invasive strategy reduced the risk of 
ischemic cardiovascular events or death from any 
cause. The trial findings were sensitive to the 
definition of myocardial infarction used.
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Figure 3. Analyses of Heterogeneity of Treatment Effect for the Primary Outcome.
Only the first event per patient was counted in these analyses. Ischemia severity was based on core-laboratory interpretation. A total of 
1266 patients did not undergo core-laboratory–interpreted computed tomographic (CT) angiography for the trial and did not have an 
available previous CT angiogram within 1 year before the trial for core-laboratory interpretation, and 923 patients had a CT angiography 
core-laboratory interpretation in which the number of diseased vessels could not be evaluated. When trial images could be interpreted 
for this variable, the number of diseased vessels on CT angiography was based on a 50% stenosis threshold. Data on CAD severity 
based on 50% stenosis exclude 4 patients with no diseased vessels. Stenosis of the proximal left anterior descending (LAD) coronary 
artery was reported when the proximal LAD segment could be evaluated on CT angiography. Patients were considered to have high at-
tainment of guideline-based medical therapy at baseline if they met all the following criteria: low-density lipoprotein cholesterol level of 
less than 70 mg per deciliter (1.8 mmol per liter) and receipt of any statin, systolic blood pressure of less than 140 mm Hg, receipt of 
aspirin or other antiplatelet or anticoagulant agent, and no smoking. Patients who were determined by the core laboratory to have mod-
erate ischemia on a nonimaging exercise-stress test did not meet ischemia eligibility, yet some such patients underwent randomization. 
This explains the discrepancy between the “no” category under ischemia eligibility (13.8%) and the “none or mild” category for the “de-
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